期刊文献+

国产Precil C3510全自动血凝分析仪检测常规凝血项目临床评价 被引量:1

Clinical evaluation of homemade Precil C3510 automatic coagulation analyzer for routine coagulation parameters
下载PDF
导出
摘要 目的评价国产Precil C3510全自动血凝分析仪(简称Precil C3510)检测常规凝血项目[凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、纤维蛋白原(Fib)、D-二聚体(DD)]临床性能及在华法林和普通肝素抗凝治疗效果监测中的应用。方法依据美国临床实验室标准化协会(CLSI)相关指南对Precil C3510检测PT、APTT、Fib、DD不精密度、抗干扰能力、线性、参考区间进行验证。同时,以STA-Compact全自动血凝分析仪(简称STA-Compact)为参考,应用Spearman相关分析、Passing-Bablok回归分析及BlandAltman图对PrecilC3510进行一致性评价。评价PrecilC3510检测口服华法林患者国际标准化比值(INR)与STA-Compact检测结果的一致性。以STA-R Evolution全自动血凝分析仪(简称STA-R Evolution)检测的抗Xa活性(0.3~0.7 IU/mL)为标准,探讨Precil C3510监测普通肝素治疗的APTT参考区间。结果Precil C3510不精密度、线性、参考区间均符合相应标准。3.2 mg/mL及更高浓度的三酰甘油对DD测定值有负干扰。2台仪器PT、Fib测定值具有较好的一致性(无系统差异、比例差异、随机差异,且偏移在临床接受区间内);APTT测定值存在系统差异[回归方程截距为-18.1216,95%可信区间(CI)为-26.0039^-12.5221]、比例差异(斜率为1.2618,95%CI为1.1234~1.4356)、随机差异(92.31%的偏移位于±1.96 s区间内)、平均偏移(-18.9%,95%CI为-22.9%^-14.9%)不在临床接受区间内(-7.5%~7.5%)。2台仪器基于各自参考区间对APTT结果的判定具有较好的一致性(Kappa=0.87,95%CI为0.74~0.99)。Precil C3510检测普通肝素抗凝治疗的APTT参考范围为62~108.1 s。2台仪器的口服华法林患者INR具有较好的一致性[35例(87.5%)患者INR差异<0.5]。结论Precil C3510在常规凝血项目检测中具有良好的分析性能,可用于华法林和普通肝素抗凝治疗的临床监测。 Objective To evaluate the clinical performance of homemade Precil C3510 automatic coagulation analyzer for routine coagulation parameters[prothrombin time(PT),activated partial thromboplastin time(APTT),fibrinogen(Fib)and D-dimer(DD)]and its application in monitoring the efficiency of warfarin and unfractionated heparin anticoagulant therapy.Methods According to the Clinical and Laboratory Standards Institute(CLSI)guidelines,the imprecision,interference,linearity and reference intervals of Precil C3510 for the determinations of PT,APTT,Fib and DD were validated.The consistency between Precil C3510 and STA-Compact automatic coagulation analyzer(STA-Compact)was evaluated by Spearman correlation,Passing-Bablok regression and Bland-Altman plot with STA-Compact as a reference system.The consistency of the international normalized ratio(INR)between Precil C3510 and STA-Compact for patients receiving warfarin therapy was evaluated.APTT monitoring range for Precil C3510 based on the standard of 0.3-0.7 IU/mL of anti-Xa activity determined by STA-R Evolution was investigated.Results The imprecision,linearity and reference intervals of Precil C3510 met the manufacturers'requirements.Triglyceride with 3.2 mg/mL and more higher concentrations had a negative effect on DD.The 2 instruments had good consistency in determining PT and Fib.There was no systematic,proportional and random differences,and the deviations were within clinical acceptance interval.APTT determined by the 2 instruments had systematic difference[regression equation intercept was-18.1216,95%confidence interval(CI)-26.0039--12.5221],proportional difference(slope was 1.2618,95%CI 1.1234-1.4356)and random difference(the bias within±1.96s accounting for 92.31%),and the average bias(-18.9%,95%CI-22.9%--14.9%)was not within the clinical acceptance interval(-7.5%-7.5%).The results of the 2 instruments had a consistency in judging APTT based on their respective reference intervals(Kappa value was 0.87,95%CI 0.74-0.99).The APTTbased unfractionated heparin anticoagulant therapeutic range of Precil C3510 was 62-108.1 s.The INR of 35 patients(87.5%)receiving warfarin therapy showed a INR difference<0.5,indicating a good correlation between the 2 instruments.Conclusions Precil C3510 has good analytical performance for routine coagulation parameters,and it can be used to monitor the anticoagulation effect of warfarin and unfractionated heparin for routine analysis.
作者 张强 林静 宗晓龙 孙光 刘军锋 ZHANG Qiang;LIN Jing;ZONG Xiaolong;SUN Guang;LIU Junfeng(Department of Clinical Laboratory,Branch of Tianjin Third Central Hospital,Tianjin 300250,China;Department of Clinical Laboratory,the Second Hospital of Tianjin Medical University,Tianjin 300211,China;Department of Clinical Laboratory,Tianjin Gong'an Hospital,Tianjin 300100,China;Department of Clinical Laboratory,TEDA International Cardiovascular Hospital,Chinese Academy of Medical Science and Beijing Union Medical College,Tianjin 300457,China)
出处 《检验医学》 CAS 2020年第6期601-608,共8页 Laboratory Medicine
关键词 血凝分析仪 性能验证 临床评价 华法林 普通肝素 抗凝治疗 Coagulation analyzer Performance verification Clinical evaluation Warfarin Unfractionated heparin Anticoagulant therapy
  • 相关文献

参考文献5

二级参考文献17

  • 1闫振宇,华宝来,马西虎,江嘉义,范连凯,王书杰,朱铁楠,白春梅,潘家绮,赵永强.672例静脉血栓栓塞症相关危险因素分析[J].中华血液学杂志,2007,28(9):579-582. 被引量:27
  • 2Kearon C,Johnson M,Mofat K,et a1.Effect of warfarin onactivated partial thromboplastin time in patients receiving eparin[].Archives of Internal Medicine.1998
  • 3.Hematology and coagulationg checklist[]..2004
  • 4EikelboomJW,Hirsh J.Monitoring unfractionated heparinwith the aPTT:time for a fresh look[].Thrombosis and Haemostasis.2006
  • 5Bates,SM,Weitz,JI,Johnston,M,Hirsch,J,Ginsberg,JS.Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range of unfractionated heparin[].Archives of Internal Medicine.2001
  • 6Smythe MA,Koerber JM.Heparin monitoring:the confusioncontinues[].Pharmacotherapy.1999
  • 7Clinical and Laboratory Standards Institute. Interference testing in clinical chemistry [ S ]. EP7- A2, CLSI,2005.
  • 8孙学青,韩景银,刘兆军.D-二聚体的临床应用[J].检验医学与临床,2013,10(2):204-205. 被引量:15
  • 9朱铁楠,赵永强.2012版易栓症诊断中国专家共识解读[J].临床血液学杂志,2013,26(2):156-157. 被引量:29
  • 10闫宏斌,郑善銮,郝晓柯.SYSMEX CS5100血凝分析仪性能评估及凝血六项参考区间的调整[J].检验医学,2014,29(9):964-968. 被引量:13

共引文献18

同被引文献12

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部